CWC
GSK icon

Carolinas Wealth Consulting’s GSK GSK Stock Holding History

Carolinas Wealth Consulting’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-248
Closed -$9.61K – 382
2025
Q1 		$9.61K Buy
248
+20
+9% +$732 ﹤0.01% 533
2024
Q4 		$7.71K Sell
228
-25
-10% -$900 ﹤0.01% 576
2024
Q3 		$10.4K Buy
253
+32
+14% +$1.31K ﹤0.01% 558
2024
Q2 		$8.51K Buy
221
+5
+2% +$210 ﹤0.01% 580
2024
Q1 		$9.34K Buy
216
+8
+4% +$330 ﹤0.01% 569
2023
Q4 		$7.78K Buy
208
+22
+12% +$790 ﹤0.01% 572
2023
Q3 		$6.64K Buy
186
+27
+17% +$958 ﹤0.01% 574
2023
Q2 		$5.72K Buy
159
+56
+54% +$2.01K ﹤0.01% 662
2023
Q1 		$3.71K Buy
103
+3
+3% +$105 ﹤0.01% 731
2022
Q4 		$3.51K Buy
+100
New +$3.33K ﹤0.01% 737
2020
Q4 		– Sell
-61
Closed -$2.8K – 927
2020
Q3 		$3K Sell
61
-54
-47% -$2.71K ﹤0.01% 635
2020
Q2 		$6K Buy
+115
New +$5.9K ﹤0.01% 377

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Carolinas Wealth Consulting's GSK Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of GSK (GSK) in Q2 2025, closing a stake of 248 shares — an estimated $9.61K sold.

Carolinas Wealth Consulting first reported a position in GSK in Q2 2020 and held it in 12 quarters. The position peaked at $10.4K in Q3 2024. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 248 GSK shares in Q2 2025, an estimated $9.61K.
  • Carolinas Wealth Consulting first reported a position in GSK in Q2 2020 and held it in 12 quarters.
  • Carolinas Wealth Consulting's GSK position peaked at $10.4K in Q3 2024.
  • 890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.